- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00004667
Phase I Study of Human Von Willebrand Factor for Von Willebrand's Disease
OBJECTIVES: I. Evaluate the effect of a new von Willebrand factor concentrate on bleeding time, in vivo recovery, and circulating half-life of the infused factor in patients with von Willebrand's disease.
II. Assess the safety of von Willebrand factor in these patients.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PROTOCOL OUTLINE: Patients receive 1 dose of von Willebrand factor concentrate. Timed blood studies are performed for the next 96 hours.
Patients are followed every 2 weeks for 16 weeks, and at 24, 36, and 52 weeks.
Study Type
Enrollment
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
PROTOCOL ENTRY CRITERIA:
- von Willebrand's disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Gilbert C. White, University of North Carolina
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 199/11955
- UNCCH-826
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Von Willebrand's Disease
-
OctapharmaActive, not recruitingVWD - Von Willebrand's DiseaseFrance
-
Fondazione Angelo Bianchi BonomiSintesi Research SrlCompletedType 3 Von Willebrand's DiseaseFinland, France, Germany, Hungary, Iran, Islamic Republic of, Italy, Netherlands, Spain, Sweden, United Kingdom
-
Assiut UniversityNot yet recruitingVWD - Von Willebrand's Disease
-
Karolinska University HospitalKarolinska Institutet; The Swedish Society of MedicineUnknownHemophilia A | Hemophilia B | Von Willebrand's DiseaseSweden
-
VWD Connect FoundationRecruitingVWD - Von Willebrand's DiseaseUnited States
-
Bioverativ, a Sanofi companyCompletedVon Willebrand's Disease (VWD)France, United States
-
Sohag UniversityRecruitingVon Willebrand's Diseased Children, Bleeding Questionnaire is DoneEgypt
-
The University of Texas Health Science Center,...WithdrawnHealthy | Von Willebrand's DisorderUnited States
-
Hemab ApSPSI CRORecruitingVon Willebrand Disease (VWD) | Von Willebrand Disease (VWD), Type 1 | Von Willebrand Disease (VWD), Type 2 | Von Willebrand Disease (VWD), Type 3 | Von Willebrand Disease, Type 2A | Von Willebrand Disease, Type 2M | Von Willebrand Disease, Type 2NUnited States, United Kingdom, Australia
-
Hemab ApSRecruitingVon Willebrand Disease (VWD) | Von Willebrand Disease (VWD), Type 1 | Von Willebrand Disease (VWD), Type 2United Kingdom, Australia
Clinical Trials on von Willebrand factor
-
University of VirginiaRecruiting
-
Hoffmann-La RocheRecruitingVon Willebrand Disease, Type 3United States, Canada, Belgium, Spain, Germany, Japan, Netherlands, United Kingdom, France, Poland, South Africa, Italy, Colombia, Sweden
-
Fondazione Angelo Bianchi BonomiSintesi Research SrlCompletedType 3 Von Willebrand's DiseaseFinland, France, Germany, Hungary, Iran, Islamic Republic of, Italy, Netherlands, Spain, Sweden, United Kingdom
-
Hoffmann-La RocheRecruitingVon Willebrand Disease, Type 3United States, Canada, Belgium, Spain, Germany, Netherlands, United Kingdom, France, Japan, South Africa, Italy, Colombia, Poland, Sweden
-
Baxalta now part of ShireCompletedVon Willebrand DiseaseUnited States, Spain, Australia, Taiwan, Czechia, Turkey, Ukraine, Netherlands, Italy, United Kingdom, Austria, Germany, Russian Federation
-
Grifols Therapeutics LLCGrifols Biologicals, LLCTerminatedHemophilia A, CongenitalUnited States, Spain, Italy, India, Canada, Russian Federation
-
TakedaAvailableVon Willebrand Disease (VWD)
-
Tirol Kiniken GmbHLFB BIOMEDICAMENTSUnknown
-
OctapharmaCompletedVon Willebrand DiseasesLebanon, Croatia, United States, Hungary, Russian Federation, Ukraine, Belarus, Bulgaria
-
OctapharmaCompletedVon Willebrand DiseasesLebanon, Croatia, United States, Belarus, Bulgaria, Hungary, Russian Federation, Ukraine